STOCK TITAN

Eikon Therapeutics (EIKN) Stock News, Feb 4, 2026

EIKN NASDAQ

Eikon Therapeutics reports company news centered on clinical-stage oncology development, financial results, public-company milestones, and capital-structure updates. Recurring developments include progress across EIK1001, EIK1003, and EIK1004, including lung cancer, prostate cancer, breast cancer, ovarian cancer, and advanced solid tumor programs.

The company’s news also covers corporate updates following its Nasdaq listing, shareholder voting matters, clinical or regulatory disclosures, and financial reporting for a late-stage biopharmaceutical issuer that operates through a single drug discovery and clinical development segment.

Rhea-AI Summary

Eikon Therapeutics (Nasdaq:EIKN) priced an upsized initial public offering of 21,177,600 shares at $18.00 per share, with gross proceeds expected to be approximately $381 million before fees. The underwriters have a 30-day option for an additional 3,176,640 shares.

Shares are expected to begin trading on the Nasdaq Global Select Market on February 5, 2026, with the offering scheduled to close on or about February 6, 2026, subject to customary closing conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Eikon Therapeutics (EIKN)?

Eikon Therapeutics (EIKN) last closed at $5.98.

What is the market cap of Eikon Therapeutics (EIKN)?

The market cap of Eikon Therapeutics (EIKN) is approximately $324.0M.